A few years ago, you couldn’t make it through a biotech investor presentation without hearing about “multiple shots on goal.” But with cash in short supply and exit strategies limited, “tightly-focused” is the new catchphrase of the day. “There’s still room for different business models,” said Sean McCarthy, senior principal at Pappas Ventures. “The question is: What type of biotech can be built today, and where does that next generation of companies come from?” The shift from broad pipelines to single products is one born of economic necessity, both for public and private biotechs.

Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).

The Florida Institute for the Commercialization of Public Research (The Institute) today announced the formation of its Strategic Advisory Board; 15 distinguished industry experts who will provide counsel on technical challenges associated with raising early stage capital and technology commercialization.